Current guidelines recommend the use of ceftriaxone and sulbactam-ampicillin for the initial treatment of community-acquired pneumonia (CAP). However, there are no clear data on these guidelines. Therefore, this systematic review and meta-analysis aims to evaluate the effectiveness of ceftriaxone and sulbactam-ampicillin in the initial treatment of CAP. The Embase, Scopus, PubMed, Ichushi, and Cumulative Index to Nursing and Allied Health Literature databases were systematically searched from inception to July 2022. The studies included patients who received ceftriaxone or sulbactam-ampicillin as the initial antibiotic therapy for CAP. The mortality and clinical cure rates were evaluated. Of the 2152 citations identified for screening, four studies were included. Results of the pooled analysis indicated no significant differences in the mortality and clinical cure rates between patients treated with ceftriaxone and those treated with sulbactam-ampicillin (mortality, odds ratio [OR]: 1.85, 95% confidence interval [CI]: 0.57–5.96; clinical cure rate, OR: 1.08, 95% CI: 0.18–6.44). This study supports the guidelines for CAP treatment, though further studies are needed to obtain a deeper understanding.

中文翻译：

---

头孢曲松和舒巴坦-氨苄青霉素作为社区获得性肺炎初始治疗的比较：系统评价和荟萃分析

目前的指南推荐使用头孢曲松和舒巴坦-氨苄青霉素作为社区获得性肺炎 (CAP) 的初始治疗。但是，没有关于这些指南的明确数据。因此，本系统评价和荟萃分析旨在评估头孢曲松和舒巴坦-氨苄青霉素在 CAP 初始治疗中的有效性。系统检索了 Embase、Scopus、PubMed、Ichushi 和 Cumulative Index to Nursing and Allied Health 文献数据库，从开始到 2022 年 7 月。这些研究包括接受头孢曲松或舒巴坦-氨苄青霉素作为 CAP 初始抗生素治疗的患者。评估死亡率和临床治愈率。在确定用于筛选的 2152 篇引文中，包括四项研究。汇总分析结果表明，接受头孢曲松治疗的患者与接受舒巴坦-氨苄青霉素治疗的患者之间的死亡率和临床治愈率没有显着差异（死亡率，优势比 [OR]：1.85，95% 置信区间 [CI]：0.57-5.96 ；临床治愈率，OR：1.08，95% CI：0.18-6.44）。该研究支持 CAP 治疗指南，但需要进一步研究以获得更深入的了解。